ACRV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 24 of 26 cases where ACRV's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACRV's RSI Oscillator exited the oversold zone, 24 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 56 cases where ACRV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +7.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRV advanced for three days, in 180 of 202 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACRV as a result. In 66 of 73 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ACRV turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In 30 of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
ACRV moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ACRV crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for ACRV entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.902) is normal, around the industry mean (2.988). P/E Ratio (-0.971) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 46 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. ACRV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IMRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 38 cases where IMRX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMRX's RSI Indicator exited the oversold zone, 23 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 59 cases where IMRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for IMRX just turned positive on October 20, 2026. Looking at past instances where IMRX's MACD turned positive, the stock continued to rise in 35 of 41 cases over the following month. The odds of a continued upward trend are 85%.
Following a +2.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMRX advanced for three days, in 224 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMRX as a result. In 80 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IMRX entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. IMRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.269) is normal, around the industry mean (2.988). P/E Ratio (-4.022) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
| ACRV | IMRX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 88% | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 84% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 90% |
| Advances ODDS (%) | 2 days ago 89% | 2 days ago 89% |
| Declines ODDS (%) | 9 days ago 87% | 9 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 89% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACRV’s FA Score shows that 0 FA rating(s) are green while IMRX’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACRV’s TA Score shows that 4 TA indicator(s) are bullish while IMRX’s TA Score has 5 bullish TA indicator(s).
ACRV (@Biotechnology) experienced а +6.10% price change this week, while IMRX (@Biotechnology) price change was +9.36% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.04%. For the same industry, the average monthly price growth was -18.13%, and the average quarterly price growth was -15.32%.
ACRV is expected to report earnings on Nov 12, 2026.
IMRX is expected to report earnings on Nov 11, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, ACRV has been loosely correlated with IMRX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ACRV jumps, then IMRX could also see price increases.
| Ticker / NAME | Correlation To ACRV | 1D Price Change % | ||
|---|---|---|---|---|
| ACRV | 100% | +1.67% | ||
| IMRX - ACRV | 50% Loosely correlated | +0.27% | ||
| ALLR - ACRV | 48% Loosely correlated | -0.62% | ||
| CRMD - ACRV | 43% Loosely correlated | +2.91% | ||
| DNA - ACRV | 41% Loosely correlated | +1.52% | ||
| ABSI - ACRV | 37% Loosely correlated | +10.69% | ||
More | ||||
A.I.dvisor indicates that over the last year, IMRX has been loosely correlated with SPRB. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if IMRX jumps, then SPRB could also see price increases.
| Ticker / NAME | Correlation To IMRX | 1D Price Change % | ||
|---|---|---|---|---|
| IMRX | 100% | +0.27% | ||
| SPRB - IMRX | 52% Loosely correlated | +3.64% | ||
| ACRV - IMRX | 49% Loosely correlated | +1.67% | ||
| CRMD - IMRX | 47% Loosely correlated | +2.91% | ||
| RAPP - IMRX | 41% Loosely correlated | -14.67% | ||
| LXEO - IMRX | 40% Loosely correlated | -0.66% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JLS | 16.22 | 0.05 | +0.31% |
| Nuveen Mortgage and Income Fund | |||
| DRLL | 44.78 | 0.03 | +0.06% |
| Strive U.S. Energy ETF (DRLL) | |||
| HMAY | 25.48 | N/A | N/A |
| Corgi U.S. Equities 100% Structured Buffer ETF (HMAY) | |||
| JBBB | 47.21 | -0.01 | -0.02% |
| Janus Henderson B-BBB CLO ETF (JBBB) | |||
| EDZ | 16.73 | -0.22 | -1.30% |
| Direxion Daily MSCI Emerging Markets Bear 3X ETF (EDZ) | |||